Cardiac Manifestations in Systemic Lupus Erythematosus: Clinical Correlates of Subclinical Echocardiographic Features

Abstract

Objectives This study aims to correlate subclinical echocardiographic features with the clinical, laboratory, and therapeutic profiles of the patients to characterize risks for systemic lupus erythematosus (SLE) cardiac diseases. Methods The study included 59 SLE patients. Demographic data, disease characteristics, and current therapies were recorded, and the anthropometric measurements and routine laboratory tests were performed. The disease activity by the SLE Disease Activity Index-2K (SLEDAI2K) and the presence of metabolic syndrome (MetS) were assessed. Two-dimensional echocardiography was performed. Results The mean age of the patients was 31.3 ± 10.5 years, and the disease duration was 5.18 ± 4.1 years. 86.4% of the patients were females. Cardiac presentations by echocardiography were mainly mitral regurgitation (33.9%), tricuspid regurgitation (32.2%), mitral thickening (18.6%), aortic thickening (13.6%), pericardial effusion (13.6%), and pulmonary hypertension (8.5%) in order of frequency. The frequency of different echocardiographic findings with respect to other clinical phenotypes showed peaks with renal disease, MetS, and leukopenia. Components of MetS (triglycerides, high systolic blood pressure) and avascular necrosis were significant predictors for pericardial diseases (OR=1.011 CI 95% 1-1.022, p=0.046, OR=1.157 CI 95% 1.025-1.307, p=0.018, and OR=74.78 CI 95% 2.52-2215.76, p=0.013, respectively), and it is likely that hydroxychloroquine was protective against them. Age of the patients was a significant predictor for tricuspid regurgitation (OR=1.063 CI 95% 1.004-1.126, p=0.036). Mucosal ulcers were negative predictors for mitral thickening and regurgitation (OR=0.2 CI 95% 0.059-0.673, p=0.009). The use of corticosteroids appeared to protect against a number of valve lesions especially tricuspid regurgitation (OR=0.299 CI 95% 0.088-1.019, p=0.054). Conclusion This study highlighted different echocardiographic features and identified clinical predictors of different cardiac pathologies aiming to determine patients at risk and improve the prognosis of SLE cardiac diseases.

Cardiac manifestations in cases with systemic lupus erythematosus: A prospective study

“…In arthritis, 20.3% cases had myalgia and 50.8% cases had oral and nasal ulcers [9] . A study by Nahla Mohamad Gaballah et al found female predominance in both the study groups i.e.…”

“…Alaa AA Mohamed et al in his study noticed mean age 31.3 years with female predominance (86.4%). The mean disease duration was 5.18 years [9] .…”

Systemic lupus erythematosus with hypothyroidism as the initial clinical manifestation: A case report

“…The association between pericardial effusion and hypothyroidism was first reported in the early 20th century ( 50 ), and has been reported successively since then ( 51-53 ). Pericardial effusion is a complication and indicator of the stage of SLE ( 54 ). Severe hypothyroidism and active SLE are known to lead to the development of pericardial effusion.…”

Constrictive Pericarditis as an Initial Manifestation of Systemic Lupus Erythematosus

“…Although all the three layers of the heart (endocardium, myocardium and pericardium) can be diseased in SLE, the most commonly reported cardiac manifestation is pericarditis [ 4 ]. In a study conducted on SLE patients without any clinically apparent heart disease, a multitude of echocardiographic abnormalities were found [ 5 ]. These included valvular lesions (47.5%), pericardial effusion (13.6%), pulmonary artery hypertension (8.5%), pericardial thickening (6.8%), impaired systolic function (3.4%) and left ventricular hypokinesia (1.7%).…”